271 related articles for article (PubMed ID: 17207947)
1. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
Brouwers J; Tack J; Augustijns P
Int J Pharm; 2007 May; 336(2):302-9. PubMed ID: 17207947
[TBL] [Abstract][Full Text] [Related]
2. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
Brouwers J; Tack J; Augustijns P
Pharm Res; 2007 Oct; 24(10):1862-9. PubMed ID: 17443397
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs.
Yuan H; Li N; Lai Y
Drug Metab Dispos; 2009 Jul; 37(7):1443-7. PubMed ID: 19372225
[TBL] [Abstract][Full Text] [Related]
4. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
6. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers.
Ingels F; Beck B; Oth M; Augustijns P
Int J Pharm; 2004 Apr; 274(1-2):221-32. PubMed ID: 15072798
[TBL] [Abstract][Full Text] [Related]
7. Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
Wire MB; Shelton MJ; Studenberg S
Clin Pharmacokinet; 2006; 45(2):137-68. PubMed ID: 16485915
[TBL] [Abstract][Full Text] [Related]
8. Food-dependent disintegration of immediate release fosamprenavir tablets: in vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system.
Brouwers J; Anneveld B; Goudappel GJ; Duchateau G; Annaert P; Augustijns P; Zeijdner E
Eur J Pharm Biopharm; 2011 Feb; 77(2):313-9. PubMed ID: 21055466
[TBL] [Abstract][Full Text] [Related]
9. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir.
Brouwers J; Tack J; Lammert F; Augustijns P
J Pharm Sci; 2006 Feb; 95(2):372-83. PubMed ID: 16374852
[TBL] [Abstract][Full Text] [Related]
10. Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies.
Stappaerts J; Geboers S; Snoeys J; Brouwers J; Tack J; Annaert P; Augustijns P
Eur J Pharm Biopharm; 2015 Feb; 90():1-7. PubMed ID: 25592324
[TBL] [Abstract][Full Text] [Related]
11. Fosamprenavir: drug development for adherence.
Hester EK; Chandler HV; Sims KM
Ann Pharmacother; 2006; 40(7-8):1301-10. PubMed ID: 16757678
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel system for estimating human intestinal absorption using Caco-2 cells in the absence of esterase activity.
Ohura K; Sakamoto H; Ninomiya S; Imai T
Drug Metab Dispos; 2010 Feb; 38(2):323-31. PubMed ID: 19923255
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
Furfine ES; Baker CT; Hale MR; Reynolds DJ; Salisbury JA; Searle AD; Studenberg SD; Todd D; Tung RD; Spaltenstein A
Antimicrob Agents Chemother; 2004 Mar; 48(3):791-8. PubMed ID: 14982766
[TBL] [Abstract][Full Text] [Related]
14. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms.
Lind ML; Jacobsen J; Holm R; Müllertz A
Eur J Pharm Sci; 2007 Dec; 32(4-5):261-70. PubMed ID: 17890067
[TBL] [Abstract][Full Text] [Related]
15. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs.
Fossati L; Dechaume R; Hardillier E; Chevillon D; Prevost C; Bolze S; Maubon N
Int J Pharm; 2008 Aug; 360(1-2):148-55. PubMed ID: 18539418
[TBL] [Abstract][Full Text] [Related]
16. Intestinal behavior of the ester prodrug tenofovir DF in humans.
Geboers S; Haenen S; Mols R; Brouwers J; Tack J; Annaert P; Augustijns P
Int J Pharm; 2015 May; 485(1-2):131-7. PubMed ID: 25747454
[TBL] [Abstract][Full Text] [Related]
17. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
Yu L; Bridgers A; Polli J; Vickers A; Long S; Roy A; Winnike R; Coffin M
Pharm Res; 1999 Dec; 16(12):1812-7. PubMed ID: 10644067
[TBL] [Abstract][Full Text] [Related]
18. A study of the intestinal absorption of an ester-type prodrug, ME3229, in rats: active efflux transport as a cause of poor bioavailability of the active drug.
Okudaira N; Tatebayashi T; Speirs GC; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Aug; 294(2):580-7. PubMed ID: 10900235
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of dendrimer prodrugs for oral drug delivery.
Najlah M; Freeman S; Attwood D; D'Emanuele A
Int J Pharm; 2007 May; 336(1):183-90. PubMed ID: 17188439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
